Physician profile
David E Riester
NPI 1306843941
$13,274.41
in general payments reported to CMS, 2019-2025
28 companies · $3,031 in 2025
The $3,031 reported for 2025 was more than what 76% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,488 · 2020: $790 · 2021: $958 · 2022: $902 · 2023: $1,771 · 2024: $3,336 · 2025: $3,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,002 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,002.38 |
| Education | $135.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,651.52 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $1,850.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,735.55 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,447.70 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $557.96 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Pharming Healthcare, INC. | $512.05 | 2019-2025 | Ruconest |
| Blueprint Medicines Corporation | $477.60 | 2022-2025 | Ayvakit |
| Amgen INC. | $454.14 | 2022-2025 | Tezspire |
| Csl Behring | $453.77 | 2019-2025 | Haegarda, Hizentra |
| Pfizer INC. | $395.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $302.45 | 2023-2025 | |
| Kaleo, INC. | $148.14 | 2019-2024 | Auvi-Q |
| Dermavant Sciences, INC. | $147.66 | 2024 | Vtama |
| Shire North American Group INC | $136.33 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $131.21 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $124.39 | 2023 | |
| Biocryst US Sales Co., LLC | $116.97 | 2021-2025 | Orladeyo |
| Aimmune Therapeutics, INC. | $108.29 | 2022 | |
| Abbvie INC. | $105.98 | 2022-2024 | Rinvoq |
| Ionis Pharmaceuticals, INC. | $71.64 | 2025 | Dawnzera, Donidalorsen |
| Regeneron Pharmaceuticals, INC. | $62.67 | 2025 | Dupixent |
| Incyte Corporation | $58.25 | 2025 | Opzelura |
| Lilly USA, LLC | $55.86 | 2025 | Ebglyss |
| Genentech USA, INC. | $53.28 | 2020-2023 | |
| Covis Pharma Gmbh | $40.56 | 2021 | |
| Cycle Pharmaceuticals INC | $29.72 | 2024 | Sajazir |
| Leo Pharma INC. | $27.48 | 2022 | |
| Alk-Abello, INC | $17.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Riester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.